KR100875611B1 - ｍＴＯＲ 억제제 및 항신생물성 알킬화제를 포함하는 제품 - Google Patents

ｍＴＯＲ 억제제 및 항신생물성 알킬화제를 포함하는 제품 Download PDF

Info

Publication number
KR100875611B1
KR100875611B1 KR1020037015721A KR20037015721A KR100875611B1 KR 100875611 B1 KR100875611 B1 KR 100875611B1 KR 1020037015721 A KR1020037015721 A KR 1020037015721A KR 20037015721 A KR20037015721 A KR 20037015721A KR 100875611 B1 KR100875611 B1 KR 100875611B1
Authority
KR
South Korea
Prior art keywords
delete delete
pat
cci
rapamycin
neoplastic
Prior art date
Application number
KR1020037015721A
Other languages
English (en)
Korean (ko)
Other versions
KR20040025923A (ko
Inventor
듀카트게리
기봉스제임스조셉쥬니어
Original Assignee
와이어쓰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 filed Critical 와이어쓰
Publication of KR20040025923A publication Critical patent/KR20040025923A/ko
Application granted granted Critical
Publication of KR100875611B1 publication Critical patent/KR100875611B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020037015721A 2001-06-01 2002-05-29 ｍＴＯＲ 억제제 및 항신생물성 알킬화제를 포함하는 제품 KR100875611B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29523601P 2001-06-01 2001-06-01
US29519001P 2001-06-01 2001-06-01
US60/295,236 2001-06-01
US60/295,190 2001-06-01
PCT/US2002/016737 WO2002098416A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Publications (2)

Publication Number Publication Date
KR20040025923A KR20040025923A (ko) 2004-03-26
KR100875611B1 true KR100875611B1 (ko) 2008-12-24

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037015721A KR100875611B1 (ko) 2001-06-01 2002-05-29 ｍＴＯＲ 억제제 및 항신생물성 알킬화제를 포함하는 제품

Country Status (17)

Country Link
EP (1) EP1392286A2 (no)
JP (1) JP2004532883A (no)
KR (1) KR100875611B1 (no)
CN (1) CN100496485C (no)
AU (2) AU2002259309B2 (no)
BR (1) BR0210101A (no)
CA (1) CA2447732A1 (no)
CO (1) CO5540294A2 (no)
EA (1) EA007530B1 (no)
HU (1) HUP0400006A2 (no)
IL (1) IL158800A0 (no)
MX (1) MXPA03010907A (no)
NO (1) NO20035317L (no)
NZ (1) NZ529877A (no)
PL (1) PL367267A1 (no)
SG (1) SG153647A1 (no)
WO (1) WO2002098416A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ307637B6 (cs) * 2001-02-19 2019-01-23 Novartis Ag 40-O-(2-Hydroxyethyl)rapamycin jako jediná účinná látka při léčení
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
AR057854A1 (es) * 2005-11-04 2007-12-19 Wyeth Corp Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
AU2006314444C1 (en) 2005-11-21 2018-01-04 Novartis Ag Neuroendocrine tumor treatment using mTOR inhibitors
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
MX2008012715A (es) * 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
MX2009009537A (es) * 2007-03-07 2009-09-16 Abraxis Bioscience Llc Nanoparticula que comprende rapamicina y albumina como agente anticancer.
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2915532B1 (en) 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
JP5681108B2 (ja) 2008-08-04 2015-03-04 ワイス・エルエルシー ４−アニリノ−３−シアノキノリンとカペシタビンの抗新生物薬の組合せ
RU2011139363A (ru) 2009-04-06 2013-05-20 ВАЙЕТ ЭлЭлСи Схема лечения рака молочной железы с использованием нератиниба
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
DE69209183T2 (de) * 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
CZ307637B6 (cs) * 2001-02-19 2019-01-23 Novartis Ag 40-O-(2-Hydroxyethyl)rapamycin jako jediná účinná látka při léčení

Also Published As

Publication number Publication date
SG153647A1 (en) 2009-07-29
NO20035317D0 (no) 2003-11-28
CN1646120A (zh) 2005-07-27
MXPA03010907A (es) 2004-02-17
EP1392286A2 (en) 2004-03-03
BR0210101A (pt) 2004-06-08
CN100496485C (zh) 2009-06-10
CA2447732A1 (en) 2002-12-12
WO2002098416A2 (en) 2002-12-12
NZ529877A (en) 2006-08-31
PL367267A1 (en) 2005-02-21
EA200301319A1 (ru) 2004-04-29
IL158800A0 (en) 2004-05-12
AU2002259309B2 (en) 2008-05-01
EA007530B1 (ru) 2006-10-27
KR20040025923A (ko) 2004-03-26
HUP0400006A2 (hu) 2004-04-28
WO2002098416A3 (en) 2003-03-13
CO5540294A2 (es) 2005-07-29
AU2008202690A1 (en) 2008-07-10
JP2004532883A (ja) 2004-10-28
NO20035317L (no) 2003-12-22

Similar Documents

Publication Publication Date Title
KR100862178B1 (ko) 라파마이신과 겜시타빈 또는 플루오로우라실과의 항신생물제 배합물
US20030008923A1 (en) Antineoplastic combinations
AU2008202690A1 (en) Antineoplastic combination
US20060030547A1 (en) Antineoplastic combinations
US7189735B2 (en) Use of CCI-779 as an antineoplastic agent
US20060035904A1 (en) Antineoplastic combinations
US20070105887A1 (en) Antineoplastic combinations of temsirolimus and sunitinib malate
RU2451524C2 (ru) Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
CA2736361C (en) Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
US20050187184A1 (en) Antineoplastic combinations
AU2002259309A1 (en) Antineoplastic combinations
AU2002227313B2 (en) Use of CCI-779 as an antineoplastic agent
AU2002257123A1 (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
AU2002227313A1 (en) Use of CCI-779 as an antineoplastic agent

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee